Apellis Pharmaceuticals, Inc.
$0
▼
-0.07%
2026-07-25 06:30:02
apellis.com
NMS: APLS
Explore Apellis Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.25 B
Current Price
$0
52W High / Low
$41.14 / $16.83
Stock P/E
39.41
Book Value
$2.92
Dividend Yield
—
ROCE
7.37%
ROE
39.71%
Face Value
—
EPS
$1
Exp Qtr EPS
—
Sector
Healthcare
APLS — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $656.01 | 15.63 | $69.14 B | 0.58% | 10.23% | 14.32% | $821.11 / $541 | $295.71 |
| 3. | Revolution Medicines, Inc. | $189.23 | — | $40.23 B | — | -57.28% | -54.06% | $193.82 / $34 | $8.28 |
| 4. | Alnylam Pharmaceuticals, Inc. | $271.77 | 61.88 | $35.72 B | — | 14.33% | 98.29% | $495.55 / $262.21 | $5.96 |
| 5. | Royalty Pharma plc | $58.83 | 40.95 | $33.88 B | 1.59% | 8.21% | 12.67% | $59.72 / $34.08 | $11.22 |
| 6. | Roivant Sciences Ltd. | $35.01 | — | $33.53 B | — | -21.06% | -6.85% | $37 / $10.9 | $6.28 |
| 7. | Incyte Corporation | $117.67 | 16.51 | $23.64 B | — | 24.67% | 29.2% | $119.6 / $69.69 | $26.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 199.91 M | 458.58 M | 178.49 M | 166.8 M | 212.53 M | — |
| Operating Profit | -51.14 M | 223.18 M | -33.29 M | -83.33 M | -26.16 M | — |
| Net Profit | -58.95 M | 215.72 M | -42.15 M | -92.22 M | -36.35 M | — |
| EPS in Rs | -0.46 | 1.68 | -0.33 | -0.72 | -0.28 | -0.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1 B | 781.37 M | 396.59 M | 75.42 M |
| Operating Profit | 55.43 M | -164.98 M | -517.12 M | -594.61 M |
| Net Profit | 22.39 M | -197.88 M | -528.63 M | -652.17 M |
| EPS in Rs | 0.17 | -1.55 | -4.13 | -5.09 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.08 B | 885.05 M | 788.73 M | 760.22 M |
| Total Liabilities | 705.11 M | 656.51 M | 594.21 M | 590.35 M |
| Equity | 370.15 M | 228.54 M | 194.52 M | 169.87 M |
| Current Assets | 1.01 B | 788.95 M | 766.33 M | 719.52 M |
| Current Liabilities | 323.6 M | 185.51 M | 247.59 M | 167.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 45.33 M | -87.87 M | -594.74 M | -513.75 M |
| Investing CF | -0.31 M | -0.4 M | -0.67 M | 59.89 M |
| Financing CF | 8.88 M | 149.24 M | 394.5 M | 365.66 M |
| Free CF | 45.01 M | -88.27 M | -595.51 M | -515.27 M |
| Capex | -0.31 M | -0.4 M | -0.77 M | -1.52 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 97.02% | 425.83% | — | — |
| Earnings Growth % | 62.57% | 18.94% | — | — |
| Profit Margin % | -25.32% | -133.29% | -864.7% | — |
| Operating Margin % | -21.11% | -130.39% | -788.38% | — |
| Gross Margin % | 84.93% | 85.25% | 92.53% | — |
| EBITDA Margin % | -19.78% | -124.85% | -818.49% | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.